Chancellor Financial Group WB LP Buys Shares of 10,937 Pfizer Inc. (NYSE:PFE)

Chancellor Financial Group WB LP bought a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 10,937 shares of the biopharmaceutical company's stock, valued at approximately $290,000.

A number of other large investors have also recently made changes to their positions in PFE. Patriot Financial Group Insurance Agency LLC grew its stake in Pfizer by 1.0% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock worth $1,027,000 after purchasing an additional 391 shares during the period. D Orazio & Associates Inc. grew its stake in Pfizer by 5.5% during the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock worth $200,000 after purchasing an additional 391 shares during the period. Lipe & Dalton grew its stake in Pfizer by 17.7% during the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock worth $71,000 after purchasing an additional 400 shares during the period. Beam Wealth Advisors Inc. grew its stake in Pfizer by 1.5% during the fourth quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company's stock worth $728,000 after purchasing an additional 401 shares during the period. Finally, Providence Capital Advisors LLC grew its stake in Pfizer by 0.4% during the fourth quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company's stock worth $3,034,000 after purchasing an additional 409 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PFE has been the subject of a number of research reports. The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Cantor Fitzgerald initiated coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective for the company. Citigroup reissued a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Stock Performance

Pfizer stock traded up $0.01 during mid-day trading on Friday, reaching $23.46. 56,576,195 shares of the company's stock were exchanged, compared to its average volume of 41,238,850. The business's fifty day simple moving average is $23.12 and its 200 day simple moving average is $25.07. The firm has a market capitalization of $133.38 billion, a PE ratio of 16.64, a P/E/G ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer's quarterly revenue was down 7.8% compared to the same quarter last year. During the same period last year, the company posted $0.82 earnings per share. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.33%. Pfizer's dividend payout ratio (DPR) is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.